# Aclaris Therapeutics, Inc. (ACRS) · Edgar & Edgarette company card

> Aclaris Therapeutics (ACRS) saw revenue fall 58.2% in FY2025 to $8 million, operating margin -976% against a -3.8% median for pharmaceutical preparations, equity 64.2% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1557746 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ACRS) · [JSON](https://www.pops4.com/boards/company/ACRS.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $8M |
| Revenue growth, 1 year | -58.2% |
| Revenue growth per year | 3.7% |
| Operating margin | -975.9% (prior year -758.2%) |
| Net margin | -829.6% |
| Operating cash flow | −$47M |
| Capital spending | $111,000 |
| Free cash flow | −$47M |
| Cash | $20M |
| Long-term debt | — |
| Total assets | $160M |
| Total equity | $103M |
| Equity ÷ assets | 64.2% |
| Return on equity | -63.0% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -18.21 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; revenue is hard to predict: its 80% range is ±69%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $7.8M (FY2025). Experience: revenue down 58.2% on the year, up 3.7% a year over 4 years; operating margin -975.9%, down from -758.2%. Soundness: equity 64.2% of assets, return on equity -63.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $1.7M and $9.6M next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $1.6M to $10.8M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -975.9% against a -3.8% median; growth -58.2% against 13.7%.

Range logged 2026-10-28, receipt d452a92adeef7acd, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 8-K · filed 2026-10-27 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1557746/000110465926119231/0001104659-26-119231-index.htm)
- 8-K · filed 2026-10-27 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1557746/000110465926118952/0001104659-26-118952-index.htm)
- 8-K · filed 2026-08-06 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1557746/000110465926092128/0001104659-26-092128-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1557746/000110465926092065/0001104659-26-092065-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1557746/000110465926091629/0001104659-26-091629-index.htm)
- 8-K · filed 2026-06-04 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1557746/000110465926070494/0001104659-26-070494-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001557746.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1557746

## Cite

POPS4, Edgar & Edgarette: Aclaris Therapeutics, Inc. (ACRS) company card, from the company's own SEC filings, accessed 2026-10-28, https://www.pops4.com/boards/company/ACRS. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.